Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STADOL PRESERVATIVE FREE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of pain (moderate to severe),Preoperative or preanesthetic medication,Supplement to balanced anesthesia,Relief of pain during labor
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 2.5–3.3 hours in adults; prolonged to 4–6 hours in elderly or hepatic impairment.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily metabolized in the liver to hydroxylbutorphanol via CYP3A4 and other enzymes.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily hepatic metabolism (glucuronidation) to inactive metabolites; renal excretion accounts for <5% unchanged drug. Approximately 70% of dose excreted in urine as metabolites, 20% in feces.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 76–80% bound to serum proteins, primarily albumin and α1-acid glycoprotein.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Volume of distribution is 1.2–1.7 L/kg, indicating extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Intramuscular: 70–80%; Subcutaneous: similar to IM. Oral: <5% due to extensive first-pass metabolism.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
For GFR 15–29 m L/min: reduce dose by 50% or increase dosing interval to every 6–8 hours. For GFR <15 m L/min: use with caution, reduce dose by 75% or administer every 8–12 hours. Hemodialysis: no supplemental dosing; not dialyzable.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval to every 6 hours. Child-Pugh Class C: avoid use; if necessary, reduce dose by 75% and monitor closely.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Children ≥12 years: 0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed. Children 2–12 years: 0.1–0.2 mg/kg/dose intravenously or intramuscularly every 3–4 hours as needed (max single dose 2 mg). Children <2 years: not recommended.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Elderly patients (≥65 years): initiate at 0.5 mg intravenously or intramuscularly every 4–6 hours; increase cautiously based on response and tolerability. Reduce total daily dose by 25–50% compared to younger adults.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and risk of abuse and dependence.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Concomitant use with CNS depressants (e.g., benzodiazepines) increases risk of sedation, respiratory depression, coma, and death,Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients,Physical and psychological dependence with chronic use,May increase intracranial pressure in patients with head injury,Risk of hypotension in hypovolemic patients,May impair ability to perform hazardous tasks,Use in renal or hepatic impairment requires dose adjustment
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Known hypersensitivity to butorphanol or any component,Patients with significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No significant food interactions. Avoid alcohol consumption.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal data at 2.5-5 times human dose. Second trimester: Same as first; prolonged use may lead to neonatal opioid withdrawal syndrome. Third trimester: Risk of neonatal respiratory depression if administered near term; may cause opioid withdrawal in newborn after chronic use.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted in human milk in low concentrations; M/P ratio not established. American Academy of Pediatrics considers butorphanol compatible with breastfeeding. Caution with high doses or prolonged use due to potential for neonatal drowsiness or withdrawal.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustments established; pharmacokinetics may be altered (increased volume of distribution, decreased peak concentrations). Use lowest effective dose for shortest duration; avoid during labor if alternative available due to risk of neonatal respiratory depression.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Stadol (butorphanol) preservative-free is for IV/IM use only; not intended for epidural or intrathecal administration due to potential neurotoxicity from the formulation. Onset of analgesia is rapid (within minutes IV). Butorphanol has ceiling effect on respiratory depression, making it safer than full mu agonists in equianalgesic doses. It can cause dysphoric reactions, especially in opioid-naive patients. Use with caution in patients with hepatic or renal impairment.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
This medication can cause drowsiness, dizziness, or lightheadedness; avoid driving or operating heavy machinery until you know how it affects you.,Do not drink alcohol or take other central nervous system depressants (e.g., benzodiazepines, other opioids) while using this medicine.,Report any severe nausea, vomiting, confusion, or hallucinations to your healthcare provider.,Butorphanol can be habit-forming; use only as prescribed.,If you are pregnant, plan to become pregnant, or are breastfeeding, inform your doctor before use.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STADOL PRESERVATIVE FREE vs ACTIQ, answered by our medical review team.
STADOL PRESERVATIVE FREE is a Opioid Analgesic that works by Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STADOL PRESERVATIVE FREE and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STADOL PRESERVATIVE FREE is: 0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STADOL PRESERVATIVE FREE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STADOL PRESERVATIVE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal data at 2.5-5 times human dose. Second trimester: Same as first; prolonged use may lead t. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.